Scholar Rock Holding Corp
Company Profile
Business description
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Contact
301 Binney Street
3rd Floor
CambridgeMA02142
USAT: +1 857 259-3860
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
289
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
stocks
Vegemite owner’s shares remain expensive on normalising profits.
stocks
Ask the analyst: Where does GYG stand following its US exit?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,051.10 | 25.30 | 0.28% |
| CAC 40 | 8,508.07 | 33.21 | 0.39% |
| DAX 40 | 25,779.31 | 198.43 | 0.78% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,679.03 | 26.16 | 0.25% |
| HKSE | 23,638.24 | 288.21 | 1.23% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,081.46 | 662.61 | -0.95% |
| NZX 50 Index | 13,697.07 | 78.65 | 0.58% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,846.20 | 27.90 | 0.32% |
| SSE Composite Index | 4,032.17 | 11.47 | -0.28% |